Addendum

Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26

Report documents

Indication:

First-line treatment of adults with unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin

Result of dossier assessment:

Unchanged after addendum: indication of considerable added benefit

05-10-2023 A G-BA decision was published.
G-BA documents on this decision

Project no.: A23-83
Commission: Commission awarded on 08.08.2023 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.